Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey

• Published in: Journal of thrombosis and thrombolysis Vol. 51; no. 2; pp. 466 - 474
• Main Authors: Uludağ, Ömer, Bektaş, Murat, Çene, Erhan, Sezer, Murat, Şahinkaya, Yasemin, Gül, Ahmet, Inanç, Murat, Öcal, Lale, Artim-Esen, Bahar
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2021; Springer Nature B.V
• Subjects: Adult; Antibodies, Antiphospholipid - analysis; Antiphospholipid antibodies; Antiphospholipid syndrome; Antiphospholipid Syndrome - complications; Antiphospholipid Syndrome - diagnosis; Autoimmune diseases; Cardiology; Cardiovascular diseases; Female; Heart Disease Risk Factors; Hematology; Humans; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - diagnosis; Male; Medicine; Medicine & Public Health; Middle Aged; Morbidity; Nephropathy; Pregnancy; Pregnancy Complications - diagnosis; Pregnancy Complications - etiology; Retrospective Studies; Risk Assessment; Risk factors; Systemic lupus erythematosus; Thrombosis; Thrombosis - diagnosis; Thrombosis - etiology; Turkey - epidemiology; Turkey; Adjusted global antiphospholipid syndrome score; Vascular thrombosis risk; Antiphospholipid syndrome
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-020-02195-4

The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). The aGAPSS was calculated for each patient as previously defined. Mean aGAPSS of the cohort was calculated as 10.2 ± 3.8. Significantly higher aGAPSS values were seen in VT ( n  = 58) and VT + PM ( n  = 29) groups when compared to PM ( n  = 11) group (10.6 ± 3.7 vs 7.4 ± 2.9, P  = 0.005; 10.7 ± 4 vs 7.4 ± 2.9, P  = 0.008, respectively), mainly due to lower frequencies of cardiovascular risk factors in PM. Higher aGAPPS values were also associated with recurrent thrombosis (11.6 ± 3.7 vs 9.9 ± 3.6, P  = 0.04). Regarding extra-criteria manifestations, patients with livedo reticularis ( n  = 11) and APS nephropathy ( n  = 9) had significantly higher aGAPSS values (12.9 ± 3.4 vs 9.9 ± 3.7, P  = 0.02; 12.4 ± 2.9 vs 10 ± 3.8, P  = 0.04, respectively). The computed AUC demonstrated that aGAPSS values ≥10 had the best diagnostic accuracy for thrombosis. Our results suggest that patients with higher aGAPSS values are at higher risk for developing vascular thrombosis (either first event or recurrence) and extra-criteria manifestations, especially livedo reticularis and APS nephropathy.